Healthcare deal points to ABS as critical tool in funding Covid economy

GlobalCapital Securitization, is part of the Delinian Group, DELINIAN (GLOBALCAPITAL) LIMITED, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 15236213

Copyright © DELINIAN (GLOBALCAPITAL) LIMITED and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions

Healthcare deal points to ABS as critical tool in funding Covid economy

BioNTech_Covid-19_vaccine-PA_575_575
19 June 2020, Baden-Wuerttemberg, Tübingen: ILLUSTRATION - A man demonstrates how a woman is vaccinated in the Institute for Tropical Medicine at the University Hospital of Tübingen. Today, the Institute of Tropical Medicine gave the first test person, a young woman, an injection of a potential active substance against the corona virus. The active substance comes from the Tübingen-based company Curevac. Photo: Christoph Schmidt/dpa | Christoph Schmidt/DPA/PA Images

Bankers Healthcare Group (BHG) is preparing an inaugural securitization backed by loans made to high-earning medical professionals. The deal is the first in a growing pipeline of securitizations from the healthcare industry, ranging from pharmaceutical drug royalties to venture capital ABS, as Covid-19 draws attention to securitization as a funding source for a critical part of the economy, writes Jennifer Kang.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login
Gift this article